Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KYNU | Q16719 | 1/20 | 0.48 |
| ▸ | CCR1 | P32246 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.42 |
| ▸ | TGM2 | P21980 | 1/20 | 0.42 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 2/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7397329 | 0.84 | KYNU (0.40) | KYNUALDH1A1ALOX15CTSKCYP3A4 | |
| SCHEMBL7216458 | 0.81 | ITGB3 (0.51) | ITGB3ITGA2B | |
| SCHEMBL7211673 | 0.80 | TACR1 (0.41) | ALDH1A1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL7211164 | 0.80 | ITGB3 (0.47) | ITGB3ITGA2BCTSL | |
| SCHEMBL7211500 | 0.79 | CCR1 (0.41) | KYNUCCR1ALDH1A1ITGB3ITGA2B | |
| SCHEMBL20522430 | 0.74 | KYNU (0.54) | KYNUCCR1ALDH1A1ALOX15CTSK | |
| SCHEMBL29440261 | 0.74 | KYNU (0.51) | KYNUALDH1A1ALOX15CTSKOPRK1 | |
| SCHEMBL20522431 | 0.74 | KYNU (0.54) | KYNUCCR1ALDH1A1ALOX15CTSK | |
| SCHEMBL6506646 | 0.72 | CASP1 (0.59) | KYNUALDH1A1ALOX15CTSKOPRK1 | |
| SCHEMBL5651104 | 0.72 | KYNU (0.53) | KYNUALDH1A1ALOX15CTSKCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6620820-B2 | Imidazole dione or one, thione derivatives as antitumor and antiinflammatory agents, also treats cardiovascular disease, nephropathies and retinopathies | HOECHST AKTIENGESELLSCHAFT (DE) | 2003-09-16 | — | — | US | disclosed |
| US-20020119999-A1 | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | HOECHST AKTIENGESELLSCHAFT | 2002-08-29 | — | — | US | disclosed |
| US-20010021708-A1 | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | WEHNER VOLKMAR (DE) | 2001-09-13 | — | — | US | disclosed |
| US-6218415-B1 | THERAPY OF BONE REABSORPTION BY OSTEOCLASTS, TUMOR GROWTH AND TUMOR METASTASIS, INFLAMMATION, CARDIOVASCULAR DISEASE, NEPHROPATHIES AND RETINOPATHIES | HOECHST AKTIENGESELLSCHAFT (DE) | 2001-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021708-A1 | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | ADGRF1, CALCR, SOST | KYNU 3220/4885CCR1 562/4885ALDH1A1 4551/4885 |
| US-20020119999-A1 | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | ADGRF1, CALCR, SOST | KYNU 3220/4885CCR1 562/4885ALDH1A1 4551/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.